OTC and citrullinemia type I: The 2013 European survey on UCDs management showed that the supplementation of BCAAs occurred only in 3% of patients with a highly variable dose up to 4 g/day protein equivalent [14], and the two most common conditions were ornithine transcarbamylase (OTC) deficiency and citrullinemia.